The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Advances Day 2019 | What to look out for at ASH 2019: MPNs
Mary Frances McMullin, MD, Queen’s University Belfast, Belfast, UK, highlights the ropeginterferon alfa-2b treatment for polycythemia vera (PV) clinical trial data she is expecting to be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition 2019. Prof. McMullin discusses the myeloproliferative neoplasms (MPNs) education session on diagnostic workflow for hereditary erythrocytosis and thrombocytosis. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
